Healthcare / Medical DevicesKOSDAQ
$6730.00
-100.00 (-1.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-12.8B · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$93.9B
P/E
29.8x
↑EV/EBITDA
10.0x
↓ROE
1.1%
↑Gross Margin
44.4%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.8%
FCF CAGR
—
FCF margin
-9.9%
FCF / Net income
-4.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $128.63B · net income $3.11B · FCF $-12.80B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $128.63B | $128.63B | $80.49B | $355.85B | $193.89B |
| Net Income | $3.11B | $3.11B | $-11.36B | $116.44B | $40.65B |
| EBITDA | $11.50B | $11.50B | $-15.87B | $158.83B | $57.28B |
| EPS | 226.00 | 226.00 | -837.00 | 8921.00 | 3168.00 |
| Gross Margin | 44.4% | 44.4% | 31.8% | 62.1% | 50.6% |
| Operating Margin | 1.9% | 1.9% | -30.5% | 40.1% | 25.4% |
| Net Margin | 2.4% | 2.4% | -14.1% | 32.7% | 21.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.59 | 2.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.80B | $-12.80B | $-51.77B | $116.71B | $30.45B |
| Returns | |||||
| ROE | 1.1% | 1.1% | -4.0% | 39.7% | 20.3% |
| Valuation | |||||
| P/E | 29.78 | 29.78 | — | — | — |
| EV/EBITDA | 10.02 | 10.02 | — | — | — |
| P/B | 0.33 | 0.33 | 0.55 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 59.8% | 59.8% | -77.4% | 83.5% | — |
| EPS Growth | 127.0% | 127.0% | -109.4% | 181.6% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
38.2%
EPS terminal req.
$597.18
Spread vs growth
88.8%
5Y implied EPS CAGR
26.2%
EPS terminal req.
$722.58
Spread vs growth
100.8%
10Y implied EPS CAGR
17.8%
EPS terminal req.
$1163.73
Spread vs growth
109.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-837.00 → 226.00
Residual
-58.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.